Mutant Allele Tumor Heterogeneity (MATH) and Head and Neck Squamous Cell Carcinoma

Head and Neck Pathology

Volumn 9, Issue 1, 2015, Pages 1-5

  Rocco, James W ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Biomarker; Head and neck squamous cell carcinoma; Intra tumor heterogeneity; Next generation sequencing; Personalized medicine; Targeted therapy

Indexed keywords

ALLELE; DNA MUTATIONAL ANALYSIS; GENETICS; HEAD AND NECK TUMOR; HIGH THROUGHPUT SEQUENCING; HUMAN; MUTATION; PROCEDURES; SQUAMOUS CELL CARCINOMA;

ALLELES; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION;

EID: 84939967561     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-015-0617-1     Document Type: Article

References (24)

1. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8(6):1095–111.
2. Bedard PL, et al. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–64.
3. Navin N, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4.
4. Park SY, et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010;120(2):636–44.
5. Russnes HG, et al. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011;121(10):3810–8.
6. Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–56.
7. Allison KH, Dintzis SM, Schmidt RA. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. Am J Clin Pathol. 2011;136(6):864–71.
8. Shah SP, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461(7265):809–13.
9. Shah SP, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9.
10. Xu X, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 2012;148(5):886–95.
11. Crockford A, et al. Implications of intratumour heterogeneity for treatment stratification. J Pathol. 2014;232(2):264–73.
12. Lim JS, Lee SC. Understanding intra-tumour heterogeneity—the next holy grail of cancer therapeutics? Ann Acad Med Singap. 2014;43(2):72–3.
13. Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–60.
14. Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013;49(3):211–5.
15. Mroz EA, et al. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer. 2013;119(16):3034–42.
16. Bonilla-Velez J, et al. Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment. Otolaryngol Clin North Am. 2013;46(4):521–43.
17. Renovanz M, Kim EL. Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Front Oncol. 2014;4:142.
18. Shackleton M, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138(5):822–9.
19. Polyak K. Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat Med. 2014;20(4):344–6.
20. Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–31.
21. Gatenby RA, et al. Adaptive therapy. Cancer Res. 2009;69(11):4894–903.
22. Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.
23. Marabelle A, et al. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20(7):1747–56.
24. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–92.